Generics Ireland-headquartered Endo International says it has reached a definitive agreement to acquire DAVA Pharmaceuticals, a privately-held US company specializing in marketed, pre-launch and pipeline generic pharmaceuticals, for $575 million in cash, with additional cash consideration of up to $25 million contingent on the achievement of certain sales milestones. 25 June 2014